RxDoctor Payments Data

Viraj Patel, MD

Family Medicine · Plymouth, INNPI 1093938979

Payments from drug & device makers

$452in general payments, 2019–2025

Across 15 payments — averaging $30.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Saluda Medical Americas, Inc.$159
  • Amgen$124
  • Pfizer$55
  • Merck$48
  • Lilly USA, LLC$31
  • Amarin Pharma, Inc.$20
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$452100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$452 in reported general payments places this provider in the 45th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$1,670,772
Medicare patients
78
Services billed
1,194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide19$29,435
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen106$3,112
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen123$2,373
Morphine Sulfate ErMorphine Sulfate22$692
Cyclobenzaprine Hcl34$451
Gabapentin12$252
Simvastatin43$250
Levothyroxine Sodium23$212
Zolpidem Tartrate26$193
Tramadol Hcl26$180
Tamsulosin Hcl16$176
Pregabalin12$156
Lisinopril26$156
Rosuvastatin Calcium19$114
Carisoprodol13$94

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$29,43519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Plymouth

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →